| [1] |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-1072.
|
| [2] |
Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death[J]. Cell Res, 2019, 29(5): 347-364.
|
| [3] |
Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future[J]. Cell Death Dis, 2020, 11(2): 88.
|
| [4] |
Dolma S, Lessnick SL, Hahn WC, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells[J]. Cancer Cell, 2003, 3(3): 285-296.
|
| [5] |
Xie Y, Hou W, Song X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3): 369-379.
|
| [6] |
Shojaie L, Iorga A, Dara L. Cell death in liver diseases: A review[J]. Int J Mol Sci, 2020, 21(24): 9682.
|
| [7] |
Pan Y, Tang P, Cao J, et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: evidence of ferroptosis induction[J]. Biochem Biophys Res Commun, 2020, 533(4): 1512-1518.
|
| [8] |
Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury[J]. Liver Int, 2017, 37(11): 1582-1590.
|
| [9] |
Galmiche A. Ferroptosis in Liver Disease//Tang D. Ferroptosis in health and disease[M]. Springer: Cham, 2019: 239-248.
|
| [10] |
Yamada N, Karasawa T, Kimura H, et al. Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure[J]. Cell Death Dis, 2020, 11(2): 144.
|
| [11] |
Yan B, Ai Y, Sun Q, et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1[J]. Mol Cell, 2021, 81(2): 355-369. e10.
|
| [12] |
Yang W, Wang Y, Zhang C, et al. Maresin1 protect against ferroptosis-induced liver injury through ROS inhibition and Nrf2/HO-1/GPX4 activation[J]. Front Pharmacol, 2022, 13: 865689.
|
| [13] |
Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Molecular pathways in protecting the liver from ischaemia/reperfusion injury: A 2015 update[J]. Clin Sci (Lond), 2015, 129(4): 345-362.
|
| [14] |
Angeli JPF, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice [J]. Nat Cell Biol, 2014, 16(12): 1180-1191.
|
| [15] |
Jiang M, Wu N, Chen X, et al. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease[J]. J Int Med Res, 2019, 47(4): 1453-1466.
|
| [16] |
Afonso MB, Castro RE, Rodrigues C. Processes exacerbating apoptosis in non-alcoholic steatohepatitis[J]. Clin Sci (Lond), 2019, 133(22): 2245-2264.
|
| [17] |
Loguercio C, De Girolamo V, Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects[J]. J Hepatol, 2001, 35(5): 568-574.
|
| [18] |
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18): 1675-1685.
|
| [19] |
Maliken BD, Nelson JE, Klintworth HM, et al. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease[J]. Hepatology, 2013, 57(5): 1806-1813.
|
| [20] |
Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity[J]. Hepatology, 2002, 36(1): 142-149.
|
| [21] |
Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019, 10(6): 449.
|
| [22] |
You M, Jogasuria A, Lee K, et al. Signal transduction mechanisms of alcoholic fatty liver disease: emer ging role of lipin-1[J]. Curr Mol Pharmacol, 2017, 10(3): 226-236.
|
| [23] |
Li LX, Guo FF, Liu H, et al. Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets[J]. Cell Mol Life Sci, 2022 , 79(4): 201.
|
| [24] |
Yang L, Wang H, Yang X, et al. Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms[J]. Signal Transduct Target Ther, 2020, 5(1): 138.
|
| [25] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, PMID: 30207593.
|
| [26] |
Louandre C, Marcq I, Bouhlal H, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells[J]. Cancer Lett, 2015, 356(2 Pt B): 971-977.
|
| [27] |
Li Y, Xia J, Shao F, et al. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis[J]. Biochem Biophys Res Commun, 2021, 534: 877-884.
|
| [28] |
Liang C, Zhang X, Yang M, et al. Recent progress in ferroptosis inducers for cancer therapy[J]. Adv Mater, 2019, 31(51): e1904197.
|
| [29] |
You A, Cao M, Guo Z, et al. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models[J]. J Hematol Oncol, 2016, 9: 20.
|
| [30] |
Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63(1): 173-184.
|
| [31] |
Nie J, Lin B, Zhou M, et al. Role of ferroptosis in hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2018, 144(12): 2329-2337.
|
| [32] |
Yang J, Gong Y, Sontag DP, et al. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines[J]. Mol Biol Rep, 2018, 45(5): 1023-1036.
|
| [33] |
Bai T, Wang S, Zhao Y, et al. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun, 2017, 491(4): 919-925.
|